Characterization of ORKA-001, a Novel Extended Half-life Monoclonal Antibody Targeting IL-23 for the Treatment of Psoriasis. J of Skin [Internet]. 2025 Mar. 17 [cited 2025 May 21];9(2):s527. Available from: https://skin.dermsquared.com/skin/article/view/3295